Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica

Abstract

Antecedentes: Las enfermedades cardiovasculares son la principal causa mundial de mortalidad y México no es la excepción. Los datos epidemiológicos obtenidos en 1990 mostraron que los padecimientos cardiovasculares representaron el 19.8% de todas las causas de muerte en nuestro país; esta cifra se incrementó de manera significativa a un 25.5% para 2015. Diversas encuestas nacionales sugieren que más del 60% de la población adulta tiene al menos un factor de riesgo para padecer enfermedades cardiovasculares (obesidad o sobrepeso, hipertensión, tabaquismo, diabetes, dislipidemias). Por otro lado,

The effects of biological sex and cardiovascular disease on COVID-19 mortality

“…CVD was defined as all individuals who declared to have a previous medical diagnosis of a heart-related disease according to the pathological entities included and recognized by the Mexican clinical practice guidelines from the Mexican Society of Cardiology and the Ministry of Health in Mexico. These included coronary heart disease (CHD), cerebrovascular disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, and pulmonary embolism ( 12 , 13 ).…”

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

“…Therapeutic goals for LDL-c and non-HDL-c levels were established according to the cardiovascular risk for each patient and by the Mexican Clinical Practice Guide for the diagnosis and treatment of dyslipidemias [ 16 ]. The goals for total cholesterol and triglycerides were established based on the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on the treatment of dyslipidemias [ 17 ].…”

“…e lipid profile consisted of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), very low-density lipoprotein (VLDL), and high-density lipoprotein cholesterol (HDL-c). e Atherogenic Index (AI) was calculated with the formula AI � Log(TG/HDL-c) and non-HDL cholesterol was calculated with the formula non-HDL � TC-HDL-c. erapeutic goals for LDL-c and non-HDL-c levels were established according to the cardiovascular risk for each patient and by the Mexican Clinical Practice Guide for the diagnosis and treatment of dyslipidemias [16]. e goals for total cholesterol and triglycerides were established based on the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on the treatment of dyslipidemias [17].…”

En busca de una escala de riesgo adecuada para los mexicanos. Las insuficiencias de la escala Globorisk

“…10 However, our group has insisted on the necessity of developing a risk scale appropriate to Mexicans, given the peculiar and distinctive features of our predominant mestizo population: high prevalence, mainly of the central type, of overweight and obesity (O/O), genetic predisposition to insulin resistance and the so-called «metabolic syndrome», atherogenic dyslipidemia, and type 2 diabetes (DM2). [11][12][13][14] A clinical guide on dyslipidemia focused on the Mexican population was recently published, 15 in which, among many debatable topics and conclusions, the use of the Globorisk tool for risk estimation in primary prevention was recommended. Although the guide is intended to be a product of a broad national consensus, many concepts and findings of several national research groups, such as ours, are not reflected in many of the recommendations and conclusions of the document mentioned above.…”